| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7696159 | BAUSCH | Treatment for basal cell carcinoma |
Apr, 2024
(24 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7696159 (Pediatric) | BAUSCH | Treatment for basal cell carcinoma |
Oct, 2024
(5 months from now) | |
Aldara is owned by Bausch.
Aldara contains Imiquimod.
Aldara has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Aldara are:
- US7696159
Aldara was authorised for market use on 27 February, 1997.
Aldara is available in cream;topical dosage forms.
Aldara can be used as works through the induction of interferon and other cytokines.
The generics of Aldara are possible to be released after 01 October, 2024.
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 27 February, 1997
Treatment: Works through the induction of interferon and other cytokines
Dosage: CREAM;TOPICAL
How can I launch a generic of ALDARA before it's drug patent expiration?
More Information on Dosage
ALDARA family patents
